ES2969366T3 - Dispositivo y métodos de administración de fármacos con microchip de dos etapas - Google Patents

Dispositivo y métodos de administración de fármacos con microchip de dos etapas Download PDF

Info

Publication number: ES2969366T3
Authority: ES; Spain
Prior art keywords: drug; reservoir; delivery device; drug delivery; wall
Prior art date: 2019-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES20816665T

Other languages

English (en)

Spanish (es)

Inventor

Robert Farra

Elizabeth Proos

Scott W James

Nicolas J Pacelli

Hong-Ren Wang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Dare MB inc

Original Assignee

Dare MB inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-11-01

Filing date

2020-10-30

Publication date

2024-05-17

2020-10-30 Application filed by Dare MB inc filed Critical Dare MB inc

2024-05-17 Application granted granted Critical

2024-05-17 Publication of ES2969366T3 publication Critical patent/ES2969366T3/es

Status Active legal-status Critical Current

2040-10-30 Anticipated expiration legal-status Critical

Links

238000012377 drug delivery Methods 0.000 title claims abstract description 92
238000000034 method Methods 0.000 title abstract description 15
239000003814 drug Substances 0.000 claims abstract description 211
229940079593 drug Drugs 0.000 claims abstract description 210
239000012528 membrane Substances 0.000 claims abstract description 84
239000013583 drug formulation Substances 0.000 claims abstract description 45
238000004891 communication Methods 0.000 claims abstract description 7
239000012530 fluid Substances 0.000 claims abstract description 7
239000000463 material Substances 0.000 claims description 37
238000009792 diffusion process Methods 0.000 claims description 17
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 16
239000000945 filler Substances 0.000 claims description 16
229960004400 levonorgestrel Drugs 0.000 claims description 16
230000004913 activation Effects 0.000 claims description 11
238000011068 loading method Methods 0.000 claims description 11
239000000758 substrate Substances 0.000 claims description 11
229940088597 hormone Drugs 0.000 claims description 8
239000005556 hormone Substances 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
238000002679 ablation Methods 0.000 claims description 7
229920001296 polysiloxane Polymers 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
229920002674 hyaluronan Polymers 0.000 claims description 5
229960003160 hyaluronic acid Drugs 0.000 claims description 5
239000003433 contraceptive agent Substances 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000012736 aqueous medium Substances 0.000 claims description 3
230000002254 contraceptive effect Effects 0.000 claims description 3
229920001477 hydrophilic polymer Polymers 0.000 claims description 2
229920002635 polyurethane Polymers 0.000 claims description 2
239000004814 polyurethane Substances 0.000 claims description 2
239000000919 ceramic Substances 0.000 claims 1
239000000599 controlled substance Substances 0.000 abstract description 2
238000007789 sealing Methods 0.000 description 21
239000002245 particle Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000001125 extrusion Methods 0.000 description 10
230000008961 swelling Effects 0.000 description 10
-1 anti-infectives Substances 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
238000001994 activation Methods 0.000 description 8
210000003722 extracellular fluid Anatomy 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
238000003466 welding Methods 0.000 description 7
230000006835 compression Effects 0.000 description 5
238000007906 compression Methods 0.000 description 5
238000013270 controlled release Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000009472 formulation Methods 0.000 description 4
239000007943 implant Substances 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000013011 mating Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
239000000560 biocompatible material Substances 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000003990 capacitor Substances 0.000 description 3
238000013461 design Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
241001465754 Metazoa Species 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
229910052581 Si3N4 Inorganic materials 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004020 conductor Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
108010011459 Exenatide Proteins 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
229940123993 Incretin mimetic Drugs 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000005219 brazing Methods 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940125693 central nervous system agent Drugs 0.000 description 1
239000003576 central nervous system agent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000004035 construction material Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000005489 elastic deformation Effects 0.000 description 1
239000013536 elastomeric material Substances 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
229960001519 exenatide Drugs 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229920002883 poly(2-hydroxypropyl methacrylate) Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000009933 reproductive health Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000008672 reprogramming Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/007—Injectors for solid bodies, e.g. suppositories
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Pathology (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicinal Preparation (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES20816665T 2019-11-01 2020-10-30 Dispositivo y métodos de administración de fármacos con microchip de dos etapas Active ES2969366T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962929432P	2019-11-01	2019-11-01
PCT/US2020/058240 WO2021087277A1 (fr)	2019-11-01	2020-10-30	Méthodes et dispositif d'administration de médicament à micropuces à deux étages

Publications (1)

Publication Number	Publication Date
ES2969366T3 true ES2969366T3 (es)	2024-05-17

Family

ID=73646420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES20816665T Active ES2969366T3 (es)	2019-11-01	2020-10-30	Dispositivo y métodos de administración de fármacos con microchip de dos etapas

Country Status (13)

Country	Link
US (1)	US20210128463A1 (fr)
EP (1)	EP4051365B1 (fr)
JP (1)	JP2022553563A (fr)
KR (1)	KR20220091506A (fr)
CN (1)	CN114728152A (fr)
AU (1)	AU2020373091A1 (fr)
BR (1)	BR112022007471A2 (fr)
CA (1)	CA3153175A1 (fr)
ES (1)	ES2969366T3 (fr)
IL (1)	IL292471A (fr)
MX (1)	MX2022005206A (fr)
WO (1)	WO2021087277A1 (fr)
ZA (1)	ZA202203976B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11464300B2 (en)	2016-05-12	2022-10-11	Arthur Snyder	Display attachment

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7070590B1 (en)	1996-07-02	2006-07-04	Massachusetts Institute Of Technology	Microchip drug delivery devices
US5797898A (en) *	1996-07-02	1998-08-25	Massachusetts Institute Of Technology	Microchip drug delivery devices
AU6639400A (en)	1999-08-18	2001-03-13	Microchips, Inc.	Thermally-activated microchip chemical delivery devices
AU770395B2 (en)	1999-11-17	2004-02-19	Boston Scientific Limited	Microfabricated devices for the delivery of molecules into a carrier fluid
AU2002326304A1 (en) *	2001-05-31	2002-12-16	Massachusetts Institute Of Technology	Microchip devices with improved reservoir opening
CN1585627A (zh) *	2001-09-14	2005-02-23	弗朗西斯J·马丁	用于持续释放治疗剂的显微制作的纳米微孔装置
US6953455B2 (en) *	2002-07-30	2005-10-11	Hospira, Inc.	Medicine delivery system
DE60336727D1 (de)	2002-08-16	2011-05-26	Microchips Inc	Vorrichtung mit kontrollierter abgabe und verfahren
AU2003278881A1 (en) *	2002-09-23	2004-04-08	Microchips, Inc.	Micro-reservoir osmotic release systems and microtube array device
WO2005016558A2 (fr) *	2003-08-04	2005-02-24	Microchips, Inc.	Procedes de liberation acceleree de matiere a partir d'un systeme reservoir
WO2006015299A2 (fr) *	2004-07-30	2006-02-09	Microchips, Inc.	Dispositif multi-reservoir pour la delivrance de medicament transdermique et la detection
EP1791643B1 (fr)	2004-09-01	2009-03-11	Microchips, Inc.	Dispositifs a reservoir dotes de plusieurs capuchons destines a la liberation controlee ou a l'exposition de contenus de reservoir
US20080076975A1 (en) *	2005-01-25	2008-03-27	Microchips, Inc.	Method and implantable device with reservoir array for pre-clinical in vivo testing
WO2007041584A2 (fr) *	2005-10-03	2007-04-12	Combinatorx, Incorporated	Capteurs implantables, pompes implantables et associations de medicaments empechant la formation de cicatrices
US20070275035A1 (en) *	2006-05-24	2007-11-29	Microchips, Inc.	Minimally Invasive Medical Implant Devices for Controlled Drug Delivery
JP2010502346A (ja) *	2006-09-08	2010-01-28	コーニンクレッカフィリップスエレクトロニクスエヌヴィ	所定量の物質の制御放出のための装置
CN100482293C (zh) *	2006-12-19	2009-04-29	重庆大学	缓释型遥控电子胶囊
US10427153B2 (en)	2011-08-25	2019-10-01	Microchips Biotech, Inc.	Systems and methods for sealing a plurality of reservoirs of a microchip element with a sealing grid
CN103906466B (zh) *	2011-08-25	2017-02-22	微芯片生物科技公司	省空间的封闭装置及其制造方法
AU2013226076B2 (en) *	2012-02-27	2017-11-16	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
CN104869888B (zh) *	2012-12-21	2017-12-19	微芯片生物技术公司	用于微创插入的可植入医疗装置
JP6387357B2 (ja)	2013-02-28	2018-09-05	マイクロチップスバイオテック，インコーポレイテッド	低侵襲挿入のための植え込み型医療デバイス
WO2016061509A1 (fr) *	2014-10-17	2016-04-21	The Broad Institute, Inc.	Compositions et procédés de traitement de la dystrophie musculaire
US10286198B2 (en) *	2016-04-08	2019-05-14	International Business Machines Corporation	Microchip medical substance delivery devices
CN110944645A (zh) *	2017-07-25	2020-03-31	塔里斯生物医药公司	治疗肿瘤转移的方法
WO2019108580A1 (fr) *	2017-11-28	2019-06-06	Massachusetts Institute Of Technology	Électroniques à résidence gastrique
US12115330B2 (en) *	2019-01-03	2024-10-15	Vibrant Ltd.	Device and method for delivering an ingestible medicament into the gastrointestinal tract of a user

2020
- 2020-10-30 ES ES20816665T patent/ES2969366T3/es active Active
- 2020-10-30 KR KR1020227016248A patent/KR20220091506A/ko active Pending
- 2020-10-30 BR BR112022007471A patent/BR112022007471A2/pt unknown
- 2020-10-30 AU AU2020373091A patent/AU2020373091A1/en active Pending
- 2020-10-30 CA CA3153175A patent/CA3153175A1/fr active Pending
- 2020-10-30 WO PCT/US2020/058240 patent/WO2021087277A1/fr unknown
- 2020-10-30 JP JP2022524110A patent/JP2022553563A/ja active Pending
- 2020-10-30 EP EP20816665.2A patent/EP4051365B1/fr active Active
- 2020-10-30 CN CN202080075060.3A patent/CN114728152A/zh active Pending
- 2020-10-30 US US17/085,424 patent/US20210128463A1/en active Pending
- 2020-10-30 IL IL292471A patent/IL292471A/en unknown
- 2020-10-30 MX MX2022005206A patent/MX2022005206A/es unknown
2022
- 2022-04-07 ZA ZA2022/03976A patent/ZA202203976B/en unknown

Also Published As

Publication number	Publication date
BR112022007471A2 (pt)	2022-07-12
US20210128463A1 (en)	2021-05-06
AU2020373091A1 (en)	2022-05-19
WO2021087277A1 (fr)	2021-05-06
KR20220091506A (ko)	2022-06-30
JP2022553563A (ja)	2022-12-23
CN114728152A (zh)	2022-07-08
MX2022005206A (es)	2022-08-10
CA3153175A1 (fr)	2021-05-06
EP4051365B1 (fr)	2023-10-18
ZA202203976B (en)	2023-10-25
IL292471A (en)	2022-06-01
EP4051365A1 (fr)	2022-09-07

Publication	Publication Date	Title
Pons-Faudoa et al.	2019	Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases
ES2294043T3 (es)	2008-04-01	Dispositivos de liberacion prolongada de medicamentos que comprenden nucleos recubiertos de medicamentos.
ES2493921T3 (es)	2014-09-12	Dispositivo MEMS para la administración de agentes terapéuticos
CN107660138B (zh)	2021-09-03	用于递送液态制剂的微针系统和用于制造微针系统的方法
ES2540247T3 (es)	2015-07-09	Dispositivo implantable de administración de medicamentos para el ojo
US7497855B2 (en)	2009-03-03	Method and device for the controlled delivery of parathyroid hormone
ES2246004T3 (es)	2006-02-01	Liberacion prolongada de un agente activo usando un sistema implantable.
CA2258898C (fr)	2005-01-11	Dispositifs d'administration de medicaments sur microplaquettes
US20070255198A1 (en)	2007-11-01	Substance Delivery Device
ES2271278T3 (es)	2007-04-16	Dispositivo para administrar microdosis de agentes en el oido.
Aj et al.	2012	Implantable drug delivery system: a review
PT840634E (pt)	2002-02-28	Sistema transcorneano para o fornecimento de medicamentos
CN1997421A (zh)	2007-07-11	药物受控递送的口腔装置及方法
KR20160124425A (ko)	2016-10-27	젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법
Patel et al.	2015	Pulsatile drug delivery system: a review
Shanmugan et al.	2015	Chronotherapeutic drug delivery systems
US6569152B2 (en)	2003-05-27	Sustained release delivery systems for solutes
ES2969366T3 (es)	2024-05-17	Dispositivo y métodos de administración de fármacos con microchip de dos etapas
BR102013004918A2 (pt)	2016-02-10	plugue pontual com matriz de confinamento energizada
US20190001053A1 (en)	2019-01-03	Subcutaneous drug delivery device with manual activation and deactivation of drug release
US20100143437A1 (en)	2010-06-10	Implantable analgesic
RU2799546C2 (ru)	2023-07-06	Способы лечения метастаза опухоли
Yadav et al.	0	Advance in Biomems Drug Delivery Devices
EP1294356B1 (fr)	2007-05-30	Systeme de delivrance a liberation lente de solutes
Matholiya et al.	0	An Approach For Controlled Drug Delivery. As Pulsatile Drug Delivery System